Table 4.

Association of CC16 mRNA Expression Levels in Bronchial Epithelial Cells with Asthma Exacerbations in Asthmatics

SARP Cross-sectional Cohort Microarray mRNA (Asthmatics, n = 128)	Exacerbation (Yes/No) in the Last 12 mo (n = 124)			Number of exacerbations in the prospective 3 yr (n = 0) RR (P Value)†
	No (n = 77)	Yes (n = 47)	OR (P Value)*
CC16 mRNA expression levels (log2)	18.2 ± 0.83	17.5 ± 1.46	0.62 (0.012)	NA

SARP Longitudinal Cohort RNAseq (Asthmatics, n = 114)	Exacerbation (Yes/No) in the Last 12 mo (n = 114)			Number of exacerbations in the prospective 3 yr (n = 92) RR (P Value)†
	No (n = 63)	Yes (n = 51)	OR (P Value)*
CC16 mRNA expression levels (ln)	15.6 ± 0.93	15.0 ± 1.02	0.55 (0.0067)	0.57 (0.015)

Definition of abbreviations: ln = natural logarithm; log2 = logarithm base 2; OR = odds ratio; RNAseq = RNA sequencing; RR = risk ratio; SARP = Severe Asthma Research Program.

^*OR and P value were generated using a logistic regression model adjusted for age, sex, body mass index, race, and batch effect.

^† RR and P value were generated using a negative binomial model adjusted for age, sex, body mass index, race, and batch effect. CC16 mRNA expression levels were logarithm base 2- and natural logarithm-transformed in the SARP cross-sectional cohort and longitudinal cohort, respectively.